MA29723B1 - Composes - Google Patents

Composes

Info

Publication number
MA29723B1
MA29723B1 MA30595A MA30595A MA29723B1 MA 29723 B1 MA29723 B1 MA 29723B1 MA 30595 A MA30595 A MA 30595A MA 30595 A MA30595 A MA 30595A MA 29723 B1 MA29723 B1 MA 29723B1
Authority
MA
Morocco
Prior art keywords
compounds
agonists
activity
treatment
pharmaceutical compositions
Prior art date
Application number
MA30595A
Other languages
English (en)
Inventor
Christopher Norbert Johnson
David Timothy Macpherson
Steven James Stanway
Geoffrey Stemp
Mervyn Thompson
Susan Marie Westaway
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0515381A external-priority patent/GB0515381D0/en
Priority claimed from GB0611469A external-priority patent/GB0611469D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29723B1 publication Critical patent/MA29723B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX DÉRIVÉS DE BENZYLPIPÉRAZINE TELS QUE LES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I), QUI PRÉSENTENT UNE ACTIVITÉ EN TANT QU'AGONISTES DU RÉCEPTEUR GPR38, AINSI QUE L'UTILISATION DESDITS COMPOSÉS OU DE COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES DANS LE TRAITEMENT DE TROUBLES GASTRO-INTESTINAUX.
MA30595A 2005-07-26 2008-01-25 Composes MA29723B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0515381A GB0515381D0 (en) 2005-07-26 2005-07-26 Compounds
GB0611469A GB0611469D0 (en) 2006-06-09 2006-06-09 Compounds

Publications (1)

Publication Number Publication Date
MA29723B1 true MA29723B1 (fr) 2008-09-01

Family

ID=37560776

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30595A MA29723B1 (fr) 2005-07-26 2008-01-25 Composes

Country Status (28)

Country Link
US (2) US8536182B2 (fr)
EP (2) EP1907374B1 (fr)
JP (1) JP4938777B2 (fr)
KR (1) KR101281435B1 (fr)
AR (1) AR054508A1 (fr)
AU (1) AU2006274212B2 (fr)
BR (1) BRPI0613987A2 (fr)
CA (1) CA2616513C (fr)
CR (1) CR9722A (fr)
CY (1) CY1113257T1 (fr)
DK (1) DK1907374T3 (fr)
EA (1) EA014061B1 (fr)
EG (1) EG26235A (fr)
ES (1) ES2390812T3 (fr)
HR (1) HRP20120833T1 (fr)
IL (1) IL188854A (fr)
JO (1) JO2747B1 (fr)
MA (1) MA29723B1 (fr)
MX (1) MX2008001211A (fr)
MY (1) MY150098A (fr)
NO (1) NO340489B1 (fr)
NZ (1) NZ565062A (fr)
PE (1) PE20070180A1 (fr)
PL (1) PL1907374T3 (fr)
PT (1) PT1907374E (fr)
SI (1) SI1907374T1 (fr)
TW (1) TWI376375B (fr)
WO (1) WO2007012479A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
MY150098A (en) * 2005-07-26 2013-11-29 Glaxo Group Ltd Benzylpiperazine derivates and their medical use
GB0524814D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
CA2633568A1 (fr) 2006-01-27 2007-08-09 M's Science Corporation Derives de piperidine et de piperazine
PL2041093T3 (pl) 2006-06-28 2010-09-30 Glaxo Group Ltd Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38
GB0723317D0 (en) * 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds
EP2401268B1 (fr) 2009-02-27 2015-07-29 RaQualia Pharma Inc Dérivés d'oxyindole ayant une activité agoniste au récepteur de la motiline
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
CN113292485B (zh) * 2021-06-08 2023-10-27 河南大学 苄基哌嗪脲类trpv1拮抗和mor激动双靶点药物及制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
TW355711B (en) 1992-11-04 1999-04-11 Chugai Pharmaceutical Co Ltd Erythromycin derivatives
JP3449766B2 (ja) 1993-11-19 2003-09-22 中外製薬株式会社 モチリンアンタゴニスト
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
JP3901239B2 (ja) 1996-03-13 2007-04-04 大正製薬株式会社 アリールアルカン誘導体
US5965578A (en) 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5734012A (en) * 1996-05-16 1998-03-31 Ohmeda Pharmaceutical Products Division Inc. Cyclic motilin-like polypeptides with gastrointestinal motor stimulating activity
DE19644195A1 (de) 1996-10-24 1998-04-30 Solvay Pharm Gmbh 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU4968997A (en) 1996-11-26 1998-06-22 Chugai Seiyaku Kabushiki Kaisha 13-membered ring macrolide compounds, medicine containing the same, and process for producing the same
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
JP3583928B2 (ja) * 1997-08-15 2004-11-04 中外製薬株式会社 フェネチルアミン誘導体
US5972939A (en) 1997-10-28 1999-10-26 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene derivatives useful as antagonists of the motilin receptor
DE19805822B4 (de) 1998-02-13 2009-02-05 Solvay Pharmaceuticals Gmbh 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6165985A (en) 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds
WO1999064436A1 (fr) * 1998-06-12 1999-12-16 Merck & Co., Inc. Clonage et identification du recepteur de la motiline
JP2000191700A (ja) * 1998-12-28 2000-07-11 Kyowa Hakko Kogyo Co Ltd 持続型消化管運動ペプチド
US20020010184A1 (en) 2000-02-18 2002-01-24 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US20020052380A1 (en) 2000-02-18 2002-05-02 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US6392040B2 (en) 2000-03-13 2002-05-21 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene compounds useful as antagonists of the motilin receptor
AU2001247357A1 (en) 2000-03-13 2001-09-24 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclobutene derivatives useful as antagonists of the motilin receptor
AU2001250820A1 (en) 2000-03-13 2001-09-24 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclohexene derivatives useful as antagonists of the motilin receptor
US6511980B2 (en) * 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
DE50204789D1 (de) 2001-05-10 2005-12-08 Solvay Pharm Gmbh Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
PA8575901A1 (es) 2002-07-18 2004-07-20 Pfizer Prod Inc Derivados de piperidina novedosos
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE602004030344D1 (de) * 2003-07-31 2011-01-13 Tranzyme Pharma Inc Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen
US7407941B2 (en) * 2003-08-26 2008-08-05 Pfizer, Inc. N-desmethyl-N-substituted-11-deoxyerythromycin compounds
US7262195B2 (en) 2003-09-17 2007-08-28 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
US7338954B2 (en) 2003-09-17 2008-03-04 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
JPWO2005063720A1 (ja) 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
WO2005077368A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique iii
WO2005077345A1 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Composes pour le traitement de la maladie du reflux gastro-oesophagien
WO2005077373A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique ii
US20070293539A1 (en) 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089515A2 (fr) 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes de traitement des synucleinopathies
EP1744751A4 (fr) 2004-03-18 2010-03-10 Brigham & Womens Hospital Traitement des synucleinopathies
JP2007529555A (ja) 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20060106060A1 (en) 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
EP1902022A1 (fr) 2005-07-12 2008-03-26 Glaxo Group Limited Derivés d hétéroaryle pipérazine en tant qu agonistes gpr38
MY150098A (en) * 2005-07-26 2013-11-29 Glaxo Group Ltd Benzylpiperazine derivates and their medical use
GB0524814D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
PL2041093T3 (pl) 2006-06-28 2010-09-30 Glaxo Group Ltd Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38
GB0723317D0 (en) 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
TW200745081A (en) 2007-12-16
MY150098A (en) 2013-11-29
JP4938777B2 (ja) 2012-05-23
KR20080037663A (ko) 2008-04-30
BRPI0613987A2 (pt) 2011-03-01
HRP20120833T1 (hr) 2012-11-30
KR101281435B1 (ko) 2013-07-02
DK1907374T3 (da) 2012-10-15
NO340489B1 (no) 2017-05-02
AR054508A1 (es) 2007-06-27
JO2747B1 (en) 2014-03-15
WO2007012479A3 (fr) 2007-04-26
IL188854A (en) 2013-08-29
EP2441763A1 (fr) 2012-04-18
ES2390812T3 (es) 2012-11-16
HK1116477A1 (en) 2008-12-24
PT1907374E (pt) 2012-11-05
IL188854A0 (en) 2008-04-13
AU2006274212B2 (en) 2011-06-09
PE20070180A1 (es) 2007-04-25
US20130317041A1 (en) 2013-11-28
US8536182B2 (en) 2013-09-17
SI1907374T1 (sl) 2012-11-30
MX2008001211A (es) 2008-03-24
PL1907374T3 (pl) 2012-12-31
CR9722A (es) 2008-04-10
NZ565062A (en) 2011-02-25
JP2009502842A (ja) 2009-01-29
AU2006274212A1 (en) 2007-02-01
CA2616513A1 (fr) 2007-02-01
EP1907374B1 (fr) 2012-08-22
WO2007012479A2 (fr) 2007-02-01
TWI376375B (en) 2012-11-11
EG26235A (en) 2013-05-07
EP1907374A2 (fr) 2008-04-09
CA2616513C (fr) 2013-02-19
NO20081014L (no) 2008-04-10
CY1113257T1 (el) 2016-04-13
EA200800421A1 (ru) 2008-06-30
EA014061B1 (ru) 2010-08-30
US20090054456A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA31457B1 (fr) N-(2-(hetaryl)aryl)arylsulfonamides et n-(2-(hetaryl)hetaryl)arylsulfonamides
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
MA30765B1 (fr) Derives innovants du thiophene
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer